Editor’s choice: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study Editorial: Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equity Hosted by: Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic Oncology Featuring: V.L. Bae-Jump, Univers...